Genomic amplification of the androgen receptor (AR) is an established mechanism 16 of antiandrogen resistance in prostate cancer. Here we show that the magnitude of 17 AR signaling output, independent of AR genomic alteration or expression level, also 18 contributes to antiandrogen resistance, through upregulation of the coactivator 19 GREB1. We demonstrate 100-fold heterogeneity in AR output within cell lines and 20
Introduction 28
Androgen receptor (AR) targeted therapy is highly effective in advanced 29 prostate cancer but is complicated by the emergence of drug resistance, called 30 castration-resistant prostate cancer (CRPC) (Shen & Abate-Shen, 2010; Watson, 31 Arora, & Sawyers, 2015) . The most common mechanism of CRPC is restored AR 32 signaling, primarily through amplification of AR (C. D. Chen et al., 2004; Robinson et 33 al., 2015) . The importance of AR amplification as a clinically important drug 34 resistance mechanism is underscored by recent data showing that AR amplification, 35 detected in circulating tumor DNA or in circulating tumor cells (CTCs), is correlated 36 with reduced clinical benefit from the next generation AR inhibitors abiraterone or 37 enzalutamide (Annala et al., 2018; Podolak et al., 2017) . 38
Genomic landscape studies of prostate cancer have revealed several 39 molecular subtypes defined by distinct genomic drivers (Berger et al., 2011; Cancer 40 Genome Atlas Research, 2015; Taylor et al., 2010) . In addition to this genomic 41 heterogeneity, primary prostate cancers also display heterogeneity in AR 42 transcriptional output, measured by an AR activity score (Hieronymus et al., 2006) . 43
Notably, these differences in transcriptional output occur in the absence of genomic 44 alterations in AR, which are generally found only in CRPC (Cancer Genome Atlas 45
Research, 2015).
One potential explanation for this heterogeneity in AR 46 Much of the work to date has focused on inter-tumoral heterogeneity. Here 50 we address the topic of intra-tumoral heterogeneity in AR transcriptional output, for 51 which we find substantial evidence in prostate cancer cell lines and in primary 52 prostate tumors. Using a sensitive reporter of AR transcriptional activity to isolate 53 cells with low versus high AR output, we show that high AR output cells have an 54 enhanced response to low doses of androgen and reduced sensitivity to 55 enzalutamide, in the absence of changes in AR mRNA and protein expression. To 56 understand the molecular basis for these differences, we performed transcriptome 57 and shRNA knockdown studies and identified three genes (GREB1, KLF8 and 58 GHRHR) upregulated in high AR output cells, all of which promote AR 59 transcriptional activity through a feed-forward mechanism. Of these, we prioritized 60 GREB1 for further characterization because GREB1 mRNA levels are increased in 61 primary prostate tumors that have high AR activity. GREB1 amplifies AR 62 transcriptional activity through a two-part mechanism: by promoting p300 63 recruitment and by enhancing AR binding to chromatin. Importantly, GREB1 64 knockdown converted high AR output cells to a low AR output state and restored 65 enzalutamide sensitivity in vivo. Collectively, these data implicate GREB1 as an AR 66 signal amplifier that contributes to prostate cancer disease progression and 67 antiandrogen resistance. 68 69 Results 70
Isolation of cells with low and high AR output but comparable AR expression 71
Previous work using a PSA promoter/GFP reporter (PSAP-eGFP) showed that 72
LNCaP prostate cancer cells display varying levels of eGFP expression. 73
Characterization of low GFP cells in this analysis revealed reduced AR levels and 74 increased expression of stem cell and developmental gene sets . 75 We explored this question in the context of the contemporary data on heterogeneity 76 in AR transcriptional output using a different AR-responsive reporter, ARR3tk-eGFP, 77
where eGFP expression is driven by the probasin promoter modified to contain 78 three AR responsive elements (Snoek et al., 1998) . LNCaP (Figure 1 ) and CWR22PC-79 EP (Figure 1-figure supplement 1) prostate cancer cells containing a single copy of 80 the reporter construct were derived by infection with lentivirus containing the 81 reporter at a low multiplicity of infection (MOI) ( Figure 1A ). Remarkably, we 82 observed >100-fold range in eGFP expression, as measured by flow cytometry, 83 despite similar levels of AR by immunofluorescence microscopy (Figure 1B ,C, Figure  84 1-figure supplement 1A). 85
We then used flow cytometry to isolate eGFP-positive cells from both ends of the 86 spectrum of AR transcriptional output, which we refer to as AR-hi (high AR output) 87 and AR-low (low AR output) cells respectively ( Figure 1C suggesting that the two reporters read out different transcriptional activities. 97 Importantly, the difference in AR output between AR-low and AR-hi cells is not 98 explained by different levels of AR expression or nuclear translocation, since both 99 were comparable in each subpopulation ( Figure 1D To elucidate the molecular basis underlying the differences in AR-low and 130 AR-hi cells, we performed RNA-sequencing and found 69 genes upregulated in AR-131 low cells and 191 genes upregulated in AR-hi cells (fold change ≥ 1.5, p < 0.05, 132 Figure 2-source data 1). In addition to enrichment of gene sets regulated by 133 androgen ( Figure 1F ), human prostate luminal and basal cell gene sets were 134 enriched in AR-hi and AR-low cells, respectively (Figure 2A ). Based on these results 135 we postulated that high AR output could be a consequence of upregulation of 136 transcriptional co-activators and/or of genes involved in luminal differentiation. 137
We therefore filtered the list of 191 genes upregulated in AR-hi cells and identified 138 33 genes annotated as co-activators or luminal genes (Figure 2-source data 2), then 139 measured the consequence of shRNA knockdown of each one on AR output in AR-hi 140 cells ( Figure 2B ). 3 of the 33 candidate genes (GREB1, GHRHR, KLF8) inhibited AR 141 activity when knocked down in AR-hi cells, with successful knockdown confirmed 142 by qRT-PCR ( Figure 2C ,D). AR knockdown served as a positive control, and ACPP 143 (one of the 30 genes that did not score) served as a negative control. Interestingly, 144 all three hits are transcriptional upregulated by DHT simulation (Figure 2E ), which 145 likely explains their increased expression in AR-hi cells. 146
Among the three, GREB1 emerged as the most compelling candidate for 147 further investigation based on interrogation of clinical datasets. Specifically, we 148 found increased expression of GREB1, but not GHRHR or KLF8, in primary prostate 149 tumors from the TCGA dataset with high AR output scores (top 5%) versus low AR 150 output scores (bottom 5%) ( Figure 2F In breast cancer, GREB1 functions as a coactivator through binding to ER and 168 recruitment of the p300/CBP complex to ER target genes (Mohammed et al., 2013) . 169
We find that GREB1 functions similarly in prostate cells, as shown by co-170 immunoprecipitation documenting AR-GREB1 interaction ( Figure 3D ) and ChIP 171 experiments showing recruitment of GREB1 to PSA and FKBP5 enhancer regions 172 ( Figure 3E ). Furthermore, AR-hi cells showed a GREB1-dependent increase in p300 173 binding ( Figure 3F Earlier we showed that AR-hi cells rapidly acquire resistance to 221 enzalutamide (refer to Figure 1I ). To determine the role of GREB1 in this drug 222 resistant phenotype, we performed knockdown experiments using the LNCaP/AR 223 xenograft. After confirming that AR activity was inhibited in AR-hi cells ( progression. Here we show that prostate cancers can amplify AR output through 239 increased expression of the dual AR/ER coactivator GREB1, in the absence of 240 genomic AR alterations. As with genomic AR amplification, increased AR output 241 driven by high GREB1 expression is also associated with enzalutamide resistance. 242
In addition to demonstrating the importance of transcriptional heterogeneity 243 in drug resistance, we also show that GREB1 amplifies AR activity by a novel two-244 part mechanism. Similar to canonical coactivators such as SRC1/2, GREB1 binds AR 245 and promotes the assembly of an active transcription complex by recruitment of 246 histone acetyl transferases such as p300/CBP (Lee & Lee Kraus, 2001 ). However, 247 GREB1 has the additional property of improving the efficiency of AR binding to DNA, 248 which further enhances AR transcriptional output. Although conceptually distinct 249 from canonical coactivators, this dual mechanism of AR activation is may not be 250 unique to GREB1. For example, TRIM24 has been shown to function as an oncogenic 251 AR cofactor and, similar to GREB1, knockdown of TRIM24 impairs recruitment of 252 AR to target genes (Groner et al., 2016) . Curiously, the effect of GREB1 on AR DNA 253 binding is not seen with ER, suggesting different conformational consequences of 254 GREB1 binding on AR and ER respectively then influence DNA binding. 255
One curious observation is the fact that prostate cancers can maintain 256 transcriptional heterogeneity as a stable phenotype, despite the fact that GREB1 257 expression drives a feed forward loop which, in principle, should result in an 258 increased fraction of high AR output cells over time. One potential explanation for 259 the ability of these populations to maintain stable proportions of high versus low AR 260 output cells at steady state is the fact that androgen has growth inhibitory effects at 261 reporter construct, and the transduced cells were sorted by mCherry flow 338 cytometry. To inactivate GREB1 gene, we single-cell cloned the cells infected with 339 lentiCRISPRv2 vector containing SgGREB1-7 or SgGREB1-8, and isolated a clone that 340 had genomic alteration at target sequence. Three clones were generated by using 341 SgGREB1-7 (SgGREB1-7-2, 7-11 and 7-12) and one clone was generated by using 342 SgGREB1-8 (SgGREB1-8-2). 343 344 shRNA screen 345 FACS-based small-scale shRNA screen with 33 selected genes was performed as 346 follows: FACS-sorted AR-hi cells were plated in 12 well plate (1.5 X 10 5 cells per 347 well, Corning, 353043) and each well was infected with pool of 3 SEPC shRNAs 348 against each gene on the following day. Cells with stable integration of hairpins 349 were selected with 2 μg/ml puromycin. 9 days after infection, half of the cells in 350 each well was used to analyze eGFP AR reporter activity using flow cytometry, and 351 the other half was subjected to qRT-PCR to determine knockdown level of the gene. Supplementary Table S8 . 448
For ChIP-seq, library preparation and RNA-seq were performed by the NYU 449 Genome Technology Center. Libraries were made using the KAPA Biosystems Hyper Peaks from shGREB1/control conditions were all merged to obtain non-overlapping 461 genomic regions, which were then used to determine conditional specific AR 462 binding. Overlapped peaks were defined as those sharing at least one base pair. To 463 generate graphs depicting AR ChIP-seq read density in ±2 kilobase regions of the AR 464 peak summits, the same number of ChIP-seq reads from different conditions were 465 loaded into the software ChAsE (Younesy et al., 2016) , and the resulting read 466 density matrices were sorted by the read densities in the shRenilla control, before 467 colouring. The read density was also used to select peaks with significant signal 468 difference between shGREB1 and controls. The criteria for assigning peaks to genes 469 have been described previously (Rockowitz & Zheng, 2015) . The MEME-ChIP 470 software (Machanick & Bailey, 2011 ) was applied to 300-bp sequences around the 471 peak summits for motif discovery, and the comparison of sequence motifs was also 472 analyzed with HOMER (http://homer.ucsd.edu/homer/). 473
Analysis of human prostate cancer datasets 474
All analysis of human prostate cancer data was conducted using previously 475 published datasets of The Cancer Genome Atlas (TCGA) (Cancer Genome Atlas 476
Research, 2015) and PCF/SU2C (Robinson et al., 2015) , which can be explored in the 477 cBioPortal for Cancer Genomics (http://www.cbioportal.org). 478
Statistics 479
For comparison of pooled data between two different groups, unpaired t tests were 480 used to determine significance. For comparison of data among three groups, one-481 way ANOVA was used to determine significance. In vitro assays represent three mice to a given xenograft assay, and experimenters were not blinded. 489
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